Henry Hagopian serves as Interim Chief Financial Officer, Vice President - Finance, Treasurer of the Company. Mr. Hagopian previously served as the Company’s Assistant Vice President and Treasurer since January 2017 and prior to that served as the Company’s Corporate Controller from October 2007 through December 2016. Prior to joining the Company, Mr. Hagopian served as Assistant Controller and Treasury Manager of CIRCOR International, Inc. from 2005 to 2007 and as Assistant Controller of Stratus Technologies from 2003 to 2005. Prior to joining Stratus, Mr. Hagopian held positions of increasing responsibility with Lucent Technologies finance organization, including the restructuring and spin-out from AT&T. Mr. Hagopian holds an M.B.A. in Management and an M.S. in Accounting from Boston College’s Carroll Graduate School of Management and a B.S. in Economics and Finance from Farleigh Dickinson University.
Henry Hagopian is 52, he's been the Interim Chief Financial Officer, Vice President - Finance et Treasurer of Organogenesis since 2020. There are 14 older and 3 younger executives at Organogenesis. The oldest executive at Organogenesis Holdings Inc. is Alan Ades, 81, who is the Independent Director.
Henry's mailing address filed with the SEC is C/O ANNOVIS BIO, INC., 1055 WESTLAKES DRIVE, SUITE 300, BERWYN, PA, 19312.
Over the last 5 years, insiders at Organogenesis have traded over $157,938,506 worth of Organogenesis stock and bought 15,146,267 units worth $65,732,558 . The most active insiders traders include Capital Managing Member Iv,..., Alan A.Erani Albert Erani D... et Glenn H Wisdom Starr Nussdorf. On average, Organogenesis executives and independent directors trade stock every 24 days with the average trade being worth of $1,067,103. The most recent stock trade was executed by Patrick Bilbo on 28 March 2024, trading 152,250 units of ORGO stock currently worth $179,655.
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic allograft wound covering and surgical barrier for application in the care of chronic and acute wounds or surgical implantation in spine, orthopedic, and sports medicine applications; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft, a dermal substitute for the treatment of DFUs; NuShield, a dehydrated placental tissue wound covering and surgical barrier applied to the target tissue to support native healing; and PuraPly Antimicrobial, an antimicrobial barrier skin substitute to treat chronic and acute wounds. Its surgical and sports medicine products comprise NuCel, a surgically implanted allograft used primarily in spinal and orthopedic surgical applications; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor, a chorionic membrane wound covering; TransCyte, a bioengineered tissue for the treatment of partial thickness burns; and Gintuit, a bioengineered bi-layered living cellular tissue for the treatment of mucogingival conditions in adults. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
Organogenesis executives and other stock owners filed with the SEC include: